Abstract: The present invention relates to an isolated mutant eubacterium comprising at least one mutation resulting in a substitution of at least one amino acid in the beta-subunit of the RNA-polymerase encoded for by the rpoB-gene providing an altered production of a product of interest when said production of a product of interest is compared to the production of the same product in an isogenic wild type strain grown at identical conditions, wherein the substitution of at least one amino acid occurs at any of positions 469, 478, 482, 485, or 487 of SEQ ID NO:2, or at the equivalent positions in any eubacterial RNA-polymererase beta-subunit family member. Another aspect of the invention relates to a process for producing at least one product of interest in a mutant eubacterium and to a use of the mutant eubacterium according to the invention for producing at least one product of interest.

Abstract: The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.

Abstract: Disclosed is a glyceroglycolipid lipase which is highly safe, can hydrolyze a neutral fat, a glycerophospholipid or a glyceroglycolipid at about pH 6, is thermally stable to some extent, can hydrolyze lecithin, cannot hydrolyze lysolecithin, can rise a bread when used singly in the production of the bread, and has no unpleasant odor. Specifically disclosed is a glyceroglycolipid lipase derived from a filamentous bacterium Aspergillus japonicus.

Abstract: Process wherein the fatty acid residues on a glyceride moiety are randomised over the terminal and middle positions, wherein the process proceeds to a conversion degree on the terminal positions, Re, ranging from 0.3 to 0.95, and wherein a conversion degree on the middle position, Ra, ranges from 0.06 to 0.75, and wherein Ra is greater than 0.32Re-0.08, the process comprises the exposure of a triglyceride fat to a catalyst comprising a lipase wherein the lipase is a Thermomyces lanuginosa lipase which has an activity of at least 250 IUN corresponding to 22 g/(g*h) at the onset of the process.

Abstract: A method for the preparation of the polyunsaturated fatty acids-containing phosphatidylserine, the method comprising: combining L-serine with a fish liver phosphatidylcholine having a polyunsaturated fatty acid to form a mixture; reacting the mixture with phospholipase D to effect transphosphatidylation of L-serine and the phosphatidylcholine having polyunsaturated fatty acids to produce the polyunsaturated fatty acids-containing phosphatidylserine.

Abstract: The invention relates to a process for production of fatty acids directly from soapstock generated in the alkali refining process including the steps of (a) adding a lipase directly to the alkaline soapstock to facilitate hydrolysis of glycerides without prior neutralization, (b) neutralizing and splitting the soaps with strong acids, and (c) separating the fatty acid phase from the aqueous phase by settling and/or centrifugation. A second embodiment is a process in which the soapstock is first neutralized and split with strong acids, followed by adding a lipase to facilitate glyceride hydrolysis, and separating the fatty acid phase. The fatty acids so obtained can be esterified with C1-C6 alcohols using a lipase that is selective for fatty acids and does not transesterify the sterolesters, and the fatty acid esters and sterolesters are separated by distillation. The sterolesters are useful as supplements for food, as pharmaceutical agents for lowering cholesterol and as biofuel and biodiesel.

Abstract: A fungal strain Beauveria species bearing accession number MTCC 5184 is disclosed. The process for the preparation of an enzyme mix including at least one enzyme selected from, but not limited to protease, carbohydrase, and lipase from the disclosed Beauveria species and uses of the enzyme mix in various areas also disclosed.

Abstract: A therapeutic composition for the treatment of the symptoms of complex regional pain syndrome and a method for preparing the therapeutic composition is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of complex regional pain syndrome, or the likelihood of an individual to develop complex regional pain syndrome is disclosed.

Abstract: The present invention relates to isolated polynucleotides having promoter activity the use of the isolated polynucleotides for the production of a polypeptide. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing a desired polypeptide using the polypeptide having promoter activity.

Abstract: The present invention relates to isolated polynucleotides having leader sequence function. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods using the polynucleotides for production of polypeptides.

Abstract: The present invention relates to isolated polynucleotides having promoter activity the juse of the isolated polynucleotides for the procuction of a polypeptide. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing a desired polypeptide using the polypeptide having promoter activity.

Abstract: Promoter regions associated with the Yarrowia lipolytica n-alkane-hydroxylating cytochrome P450 (ALK2) gene are disclosed and have been found to be particularly effective for the expression of heterologous genes in yeast. These promoter regions will be useful for driving high-level expression of genes involved in the production of omega-3 and omega-6 fatty acids.

Abstract: In an alcohol fermentation process, oil derived from biomass is hydrolyzed into an extractant available for in situ removal of a product alcohol such as butanol from a fermentation broth. The glycerides in the oil can be catalytically (e.g., enzymatically) hydrolyzed into free fatty acids, which form a fermentation product extractant having a partition coefficient for a product alcohol greater than a partition coefficient of the oil of the biomass for the product alcohol. Oil derived from a feedstock of an alcohol fermentation process can be hydrolyzed by contacting the feedstock including the oil with one or more enzymes whereby at least a portion of the oil is hydrolyzed into free fatty acids forming a fermentation product extractant, or the oil can be separated from the feedstock prior to the feedstock being fed to a fermentation vessel, and the separated oil can be contacted with the enzymes to form the fermentation product extractant.

Abstract: Promoter regions associated with the Yarrowia lipolytica peroxisomal 2,4-dienoyl-CoA reductase (SPS19) gene are disclosed and have been found to be particularly effective for the expression of heterologous genes in yeast. These promoter regions will be useful for driving high-level expression of genes involved in the production of omega-3 and omega-6 fatty acids.

Abstract: The present invention provides fungal proteases and improved fungal strains that are deficient in protease production.

Abstract: A method and system for the enzymatic treatment of a lipid containing feedstock comprises contacting the feedstock with a processing aid, then causing the feedstock to pass at a substantially constant flow rate through a treatment system comprising a plurality of enzyme-containing fixed bed reactors connected to one another in series. The fixed bed reactors can be individually serviceable, the flow rate of the feedstock remaining substantially constant through the system when one of the fixed bed reactors is taken offline for servicing. In the most preferred embodiment, the processing aid is a substantially moisture-free silica. The processing aid can be placed in one or more of the fixed bed reactors, disposed above the enzyme in the reactor, or it can be in a pre-treatment system which can comprise one or more reactors.

Abstract: The application is based on the surprising finding that proteins regulated by increased c-myc activity in the liver can be used as sis and/or treatment monitoring of cancer and dysplasia, in particular of liver cell dysplasia and hepatocellular carcinoma (HCC), and wherein the proteins are selected from a first group consisting of Polymeric immunoglobulin receptor, Phosphatidylinositol—glycan—specific phospholipase D, Alpha—fetoprotein, Antithrombin 3, Apolipoprotein E, Apolipoprotein M, Fibrinogen beta-chain, Haptoglobin, Paraoxonase 1, Retinol binding protein, Serum amyloid P- component, Transthyretin, or from a second group consisting of Afamin, Glutathione peroxidase 3, Hemopexin, Major urinary protein, Serine protease inhibitor A3K. Consequently, medical uses of said proteins, of corresponding compositions, of corresponding antibodies, of corresponding siRNA and of corresponding nucleotide sequences are claimed. Also claimed are corresponding kits and corresponding methods and procedures.

Abstract: The present invention relates to methods for diagnosing cornification disorders and metabolic diseases. More specifically, the present invention relates to an in vitro method for diagnosing and/or predicting a cornification disorder in a subject, comprising determining the presence or the absence of a genetic variation in the Patatin-like phospholipase domain-containing protein 1 (PNPLA1) gene sequence in a biological sample from said subject, as compared with the PNPLA1 gene sequence of a healthy non-carrier subject, wherein the presence of said genetic variation indicates that said subject suffers from or is at risk of suffering from said cornification disorder. The method according to the invention allows for example diagnosing ichthyosis in dogs of the Golden Retriever breed.

Abstract: A substrate or coating is provided that includes a lipase with enzymatic activity toward a component of a fingerprint. Also provided is a process for facilitating the removal of fingerprints is provided wherein an inventive substrate or coating including a lipase is capable of enzymatically degrading of one or more components of the fingerprint to facilitate fingerprint removal from the substrate or said coating. Applying heat to the substrate or coating increases the rate of fingerprint removal.

Abstract: The present invention relates to a cell suitable for production of one or more fermentation product from a sugar composition comprising glucose, galactose, arabinose and xylose, wherein the cell comprises two to fifteen copies of one or more xylose isomerase gene or two to fifteen copies of one or more xylose reductase and xylitol dehydrogenase, and two to ten copies of araA, araB and araD, genes, wherein these genes are integrated into the cell genome.

Abstract: Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a member of the triacylglycerol lipase family or which effect the enzymatic activity of the enzyme.

Abstract: Method for producing Yarrowia lipolytica acid-resistant recombinant lipase utilizing a culture medium without any products of animal origin or non-characterized mixtures such as tryptone, peptone or lactoserum, in addition to its uses. Recombinant strain of Yarrow lipolytica producing an excessive amount of lipase Lip2 referred to as YL-LIP2-6C and filed with the Collection Nationale de Cultures de Microorganismes (C.N.C.M.) under number I 3542, on Dec. 15 2005 and its uses.

Abstract: The present invention provides various GH61 protein variants comprising various amino acid substitutions. The GH61 protein variants have an improved ability to synergize with cellulase enzymes, thereby increasing the yield of fermentable sugars obtained by saccharification of biomass. In some embodiments, sugars obtained from saccharification are fermented to produce numerous end-products, including but not limited to alcohol.

Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.

Abstract: Fatty acid alcohol esters that may be used as biodiesel are synthesized from microbially produced alcohol and fatty acids using an in situ process. The process utilizes a catalyst capable of esterifying the alcohol and fatty acid products of microorganisms, which are produced from renewable resources.

Abstract: The invention relates to a process for the production of cells which are capable of converting arabinose, comprising the following steps: a) Introducing into a host strain that cannot convert arabinose, the genes AraA, araB and araD, this cell is designated as constructed cell; b) Subjecting the constructed cell to adaptive evolution until a cell that converts arabinose is obtained, c) Optionally, subjecting the first arabinose converting cell to adaptive evolution to improve the arabinose conversion; the cell produced in step b) or c) is designated as first arabinose converting cell; d) Analysing the full genome or part of the genome of the first arabinose converting cell and that of the constructed cell; e) Identifying single nucleotide polymorphisms (SNP's) in the first arabinose converting cell; and f) Using the information of the SNP's in rational design of a cell capable of converting arabinose; g) Construction of the cell capable of converting arabinose designed in step f).

Abstract: A method and system for the enzymatic treatment of a lipid containing feedstock comprises contacting the feedstock with a processing aid, then causing the feedstock to pass at a substantially constant flow rate through a treatment system comprising a plurality of enzyme-containing fixed bed reactors connected to one another in series. The fixed bed reactors can be individually serviceable, the flow rate of the feedstock remaining substantially constant through the system when one of the fixed bed reactors is taken off line for servicing. In the most preferred embodiment, the processing aid is a substantially moisture-free silica. The processing aid can be placed in one or more of the fixed bed reactors, disposed above the enzyme in the reactor, or it can be in a pre-treatment system which can comprise one or more reactors.

Abstract: The invention relates to a method of preparing a variant of a parent polypeptide comprising: (a) providing an amino acid sequence of a parent polypeptide; (b) substituting at least one amino acid residue at a position in the sequence corresponding to any of positions: 41, 83, 129, 207 or 284 in SEQ ID No: 2; (c) selecting a variant with lipolytic activity, which compared to the parent polypeptide has improved stability, and has an amino acid sequence with at least 60% identity to the mature polypeptide of SEQ ID No: 2; and (d) recovering the variant.

Abstract: The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.

Abstract: The present invention relates to a process for enzymatic lipase interesterification of oils containing a chelating agent by sequential or simultaneous treatment with a base.

Abstract: Disclosed is a process comprising (1) forming an aqueous mixture comprising a microbial composition and solid chitin, wherein said microbial composition comprises one or more microbes that produce chitin digesting enzymes; and (2) fermenting the mixture for a time sufficient to enzymatically digest all or part of the chitin to form a fermented mixture comprising chitosan and glucosamine. In some embodiments, the chitin is derived from the biodegradation of chitin containing marine Arthropods. In other embodiments, the chitin and other components contained in fungi, filamentous fungi and yeast can be obtained, for example, by the biodegradation of chitin containing fungi, filamentous fungi, yeast and/or insects, preferably using HQE for the digestion. In some embodiments, the process is carried out with a solution that already contains chitosan and/or glucosamine such as HYTb, the aqueous fraction obtained from the biodegradation of chitin containing organisms.

Abstract: Diols produced in fermentation are processed in broth by esterification of the product diol with a carboxylic acid (e.g., fatty acid) and a catalyst (e.g., lipase) capable of esterifying the product diol, such as 1,3-propanediol, with the carboxylic acid to form the diol esters. The diol esters can be extracted from the broth, and the product diol recovered from the diol esters. The carboxylic acid can also serve as an extractant for removal of the diol esters from the fermentation medium.

Abstract: The storage stability of a serine hydrolase acting on ester bonds in a formulation without a protease can be improved by incorporating a serine protease inhibitor.

Abstract: Method for producing Yarrowia lipolytica acid-resistant recombinant lipase utilizing a culture medium without any products of animal origin or non-characterized mixtures such as tryptone, peptone or lactoserum, in addition to its uses. Recombinant strain of Yarrow lipolytica producing an excessive amount of lipase Lip2 referred to as YL-LIP2-6C and filed with the Collection Nationale de Cultures de Microorganismes (C.N.C.M.) under number I 3542, on Dec. 15 2005 and its uses.

Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.

Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.

Abstract: A reaction medium for enzyme-catalyzed reactions is provided, comprising an oil-in-water emulsion including water, an emulsifier, an oil phase and at least one interfacially active enzyme, where the emulsion is produced by the phase inversion temperature process and has a droplet size of 50 to 400 nm. A method for the enzyme-catalyzed esterification, transesterification or hydrolysis of fatty acid alkyl esters and/or triglycerides is also provided where the oil-in-water emulsion is used as the reaction medium.

Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.

Abstract: The invention relates to a Talaromyces transformant comprising one or more recombinant gene, capable of producing cellulase in the absence of cellulase inducer in a glucose medium, having a cellulase activity of 2 WSU/ml or more, in 16 times or more diluted supernatant or broth.

Abstract: The present invention relates to a newly identified lipase belonging to the Ustilaginaceae family of Basidomycetes and variants thereof. The invention also relates to polynucleotides encoding the lipase and the variants thereof. The invention further relates to procedures for producing the lipase, and variants thereof, polypeptides and polynucleotides. The invention further relates to lipase variants with an increased trans-selectivity. The invention further relates to lipase variants with a preference for long chain fatty acid esters or carboxylic acid moieties with a chain length greater than C12. The invention further relates to a method of reducing, or eliminating, trans-fatty acids from liquid oil stable enough for frying systems.

Abstract: The present invention relates to alpha-amylase variants, polynucleotides encoding the variants and nucleic acid constructs, vectors, and host cells comprising the polynucleotides, and methods of using the variant enzymes.

Abstract: The invention relates to an isolated plant GDSL-lipase polypeptide differentially expressed between the different steps of the plant development and/or the different tissues of the plant, a nucleic acid molecule encoding it, and a plant or part of plant genetically engineered to not express it at least partially.

Abstract: The present invention relates to alpha-amylases, nucleic acids encoding the alpha-amylases, methods of producing the alpha-amylases, and methods of using the alpha-amylases.

Abstract: The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. Polypeptides, including enzymes and antibodies, and nucleic acids of the invention can be used in industrial, experimental, food and feed processing, nutritional and pharmaceutical applications, e.g., for food and feed supplements, colorants, neutraceuticals, cosmetic and pharmaceutical needs.

Abstract: The present invention relates to alpha-amylase variants, polynucleotides encoding the variants and nucleic acid constructs, vectors, and host cells comprising the polynucleotides, and methods of using the variant enzymes.

Abstract: The present invention relates to a new wild-type lipase, its nucleic acid sequences and the amino acid sequences thereof. This new lipase shows washing performance in the form of wild-type. The present invention also relates to the method for producing the lipase and the uses of the lipase in baking.

Abstract: The present invention is related to a fungal serine protease enzyme, which said enzyme has serine protease activity and comprises an amino acid sequence of Malbranchea ALKO4122 mature protease as defined in SEQ ID NO:18 or an amino acid sequence having at least 66% identity to the amino acid sequence of SEQ ID NO:18. Also disclosed is an isolated nucleic acid molecule, comprising a polynucleotide sequence which encodes a fungal serine protease enzyme, nucleic acid sequences encoding said protease, a host cell and a process of producing a polypeptide having serine protease activity. Said protease is useful as an enzyme preparation applicable in detergent compositions and for treating fibers, wool, hair, leather, or silk, for treating food or feed, or for any applications involving modification, degradation or removal of proteinaceous material.

Abstract: Promoter regions associated with the Yarrowia lipolytica esterase/lipase (EL1) gene are disclosed and have been found to be particularly effective for the expression of heterologous genes in yeast. These promoter regions will be useful for driving high-level expression of genes involved in the production of omega-3 and omega-6 fatty acids.

Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.